AI's impact on cardiology continues to grow, leading to $1.6B in business deals in 2021 alone

"Interest in artificial intelligence (AI) solutions capable of diagnosing cardiovascular disease is on the rise, according to a new report from the data analysis company GlobalData.

The report noted that 151 different deals involving AI have hit the cardiovascular devices market since 2020. In 2021 alone, these deals totaled nearly $1.6 billion.

“The continued investment in the development of AI-based cardiology tools reflects the growing potential of AI for manufacturers and cardiologists,” Jacob Fletcher, a medical analyst with GlobalData, said in a statement. “Significant research efforts will be needed to support its adoption into practice, as patient benefits will need to be clearly demonstrated.”

The report highlighted this ongoing trend by pointing to Cleerly’s recent financing success—the New York City-based startup raised $192 million based on its success with using AI to interpret cardiac CT exams—and the collaboration between Novartis and AI specialists Anumana focused on AI-powered electrocardiogram assessments...." Lire la suite